ecrin-mdr-crcClinical2020IPD Sharing (as of November 2022): Yes Description: The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research. Time frame: Data can be shared no earlier than 1 year following the date of publication Access Criteria: Contact the Partners Innovations team at http://www.partners.org/innovation Additional information available: Study Protocol, Statistical Analysis Plan, Informed Consent FormColorectal AdenomaGastrointestinal MicrobiomeColorectal CancerColorectal NeoplasmsEndoscopic SurgeryAdenomaEicosapentaenoic AcidColorectal AdenomaGastrointestinal MicrobiomeColorectal CancerColorectal NeoplasmsEndoscopic SurgeryAdenomaEicosapentaenoic AcidInterventionalhttps://newmdr.ecrin.org/Study/2326011United States3Mucosal TissueEicosapentaenoic acid ethyl esterColonoscopic SurgeryECRIN MDRCompletedfalsePRevention Using EPA Against coloREctal CancerThis research study is evaluating the effect of AMR101 as a possible chemopreventive agent to reduce risk of colorectal cancer in individuals with a history of colorectal adenoma. - The name of the study drug involved in this study is: -- AMR101 (VASCEPA).2020-03-152326011NCT04216251